TOP STORIES

• REGULATORY Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
  February 16, 2023

• REGULATORY Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
  February 16, 2023

• BUSINESS As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities
  February 15, 2023

• BUSINESS BMS Mulls CAR-T Manufacturing in Japan, Definitive Plans Expected by Year-End
  February 14, 2023

• BUSINESS Asahi Kasei to Push Teribone Auto-Injector, but AG Remains an Option: President
  February 13, 2023

• REGULATORY Japan Cancels 140 Million-Plus Dose Order of Novavax’s COVID Vaccine
  February 13, 2023

• REGULATORY Expert Panel’s Proposal Likely to Involve “2-Stage” Reform, Touch on Funding Too: Chairman
  February 10, 2023

• BUSINESS Kyowa Kirin Has No Plans to Launch Biosame of G-Lasta: President
  February 10, 2023

• REGULATORY Chuikyo Talks Over Sales Criteria to Trigger Possible Xocova Re-Pricing; Is 3-Month-Based Estimate an Overestimate?
  February 9, 2023

• BUSINESS CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
  February 8, 2023

• BUSINESS Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
  February 7, 2023

• REGULATORY Expert Panel Member Sakamaki Wants Pricing Overhaul to Push Generic Industry Consolidation
  February 6, 2023

• BUSINESS Astellas EVP Okamura to Become CEO in April
  February 6, 2023

• BUSINESS Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
  February 6, 2023

• BUSINESS Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
  February 3, 2023

• REGULATORY Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
  February 2, 2023

• BUSINESS Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
  February 1, 2023

• BUSINESS Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
  January 31, 2023

• BUSINESS Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
  January 31, 2023

• REGULATORY Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
  January 30, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• …
• Next ›
• 最終 »